Related by context. All words. (Click for frequent words.) 73 blinded placebo controlled 71 dose dose escalation 70 placebo controlled randomized 70 blind multicenter 70 masked placebo controlled 69 controlled multicenter 68 multicenter randomized placebo controlled 68 multicenter randomized double 68 prospective randomized placebo 68 prospective randomized multicenter 68 blinded placebo 68 blind randomized 67 randomized multicenter 67 multicenter randomized 67 active comparator 67 randomized blinded 67 double blinded placebo 67 randomized placebo controlled 67 blinded randomized 66 ascending doses 66 double blinded randomized 66 multicentre randomized double 66 dose titration 66 Phase III randomized 66 randomized 65 placebo controlled clinical 65 label dose titration 65 randomized #:# 65 placebo controlled 64 blind randomized placebo 64 randomized crossover 64 blinded randomized placebo controlled 64 dose escalation phase 64 multicenter multinational 64 multicentre randomized 63 randomized controlled 63 placebo controlled Phase III 63 randomized multicentre 63 nonrandomized 63 ascending dose 63 multicenter randomized controlled 63 placebo controlled Phase 63 randomized #:#:# 63 multicentre 63 blind randomized controlled 63 prospective multicenter 63 randomized double 63 blind placebo controlled 62 dosing cohort 62 double blind placebo 62 dose escalation 62 randomized multicenter trial 61 desvenlafaxine succinate 61 prospectively defined 61 randomized placebo 61 prospective randomized 61 Primary endpoints 61 trials RCTs 61 multicenter placebo controlled 61 oral rivaroxaban 61 dose escalation Phase 61 blind multicentre 61 prospective randomized controlled 61 dosing cohorts 61 placebo controlled dose escalation 61 atazanavir ritonavir 61 prospective observational 61 bolus dose 61 adjunctive placebo 61 Phase III randomized controlled 61 prospective multicenter randomized 60 postintervention 60 phase Ib 60 HCV RESPOND 2 60 #mg/day [001] 60 VICTOR E1 60 dose regimens 60 relapsed MM 60 insulin detemir 60 Phase 2b randomized 60 sequential dose escalation 60 relapsed myeloma 60 Randomised 60 metastatic HRPC 60 thorough QT 60 nab paclitaxel 60 multiple ascending dose 60 randomisation 60 placebo controlled trials 60 overnight polysomnography 60 achieved statistical significance 60 single ascending dose 60 dose cohort 59 pharmacokinetics PK 59 titration phase 59 PRECiSE 59 eszopiclone 59 CIMZIA TM 59 darunavir ritonavir 59 unblinded 59 label multicenter 59 multicentre prospective 59 AIR CF1 59 intravitreal injection 59 randomized Phase IIb 59 placebo controlled clinical trials 59 #:# randomization 59 telaprevir dosing 59 ROCKET AF 59 dose escalation study 59 Phase IIIb 59 placebo controlled studies 59 PREZISTA r 59 timepoints 59 CIMZIA TM certolizumab pegol 59 safety tolerability pharmacokinetics 59 venlafaxine XR 59 ritonavir boosted 59 prospective nonrandomized 59 multicenter 59 pegylated interferon alfa 2b 59 OPT CHF 58 intermittent dosing 58 mg/m2 dose 58 mg BID 58 CHOP chemotherapy 58 treatment naive genotype 58 landmark ATHENA 58 BRIM2 58 Phase 2b study 58 mg kg dose 58 comparator arm 58 randomized controlled Phase 58 Pegasys plus Copegus 58 mg administered orally 58 dosing intervals 58 administered subcutaneously 58 PRIMO CABG 58 low dose cytarabine 58 RLAI 58 Cloretazine 58 APTIVUS r 58 multicenter Phase III 58 EURIDIS 58 noninferiority 58 bupropion SR 58 observer blinded randomized 58 SIMPADICO 58 Randomized controlled 58 randomized clinical 58 rapid virologic response 58 GAMMAGARD 58 phase IIb clinical 58 multicenter Phase II 58 RRMS patients 58 tapentadol ER 58 DCCT 58 Naive Patients 58 PREZISTA ritonavir 57 retrospective cohort 57 divalproex sodium 57 blind randomized multicenter 57 MIRCERA 57 AIR CF3 57 label dose escalation 57 Randomized Placebo Controlled 57 mg dose 57 dose escalation trial 57 teriflunomide 57 eosinophilic asthma 57 galiximab 57 randomized controlled multicenter 57 FFNS 57 Betaferon ® 57 pegnivacogin 57 CHAMPION PCI 57 Randomized 57 Placebo controlled 57 weekly subcutaneous injections 57 MIRAPEX ER 57 zonisamide SR 57 secondary efficacy endpoints 57 TMC# C# 57 recurrent malignant glioma 57 symptomatic BPH 57 mg QD 57 Dose escalation 57 dosage regimens 57 bolus injection 57 patients evaluable 57 evaluating Xcytrin 57 peginterferon 57 8mg/kg 57 Traficet EN 57 fosbretabulin 57 phase IIa 57 AVOREN 57 recurrent glioblastoma multiforme 57 DLTs 57 ribavirin RBV 57 EmbraceAC 57 subcutaneously administered 57 sorafenib Nexavar ® 57 oral olanzapine 57 de novo kidney transplant 57 3mg/kg 57 MIRAPEX 57 viral kinetic 57 MGd 57 RE LY ® 57 CIMZIA ™ 57 IFN α 57 ADVANCE PD 57 IMPACT DCM 57 PEGINTRON TM 57 docetaxel chemotherapy 56 HCV SPRINT 56 Randomized Phase 56 antiretroviral naïve 56 dyskinesia PD LID 56 multinational multicenter randomized 56 VNP#M 56 inhalations twice 56 dose escalation clinical 56 F FDG PET 56 opioid naive 56 AZILECT R 56 PEG IFN 56 Phase 1b clinical 56 TAXUS ATLAS 56 intravenous bolus 56 Phase III placebo controlled 56 intravenous dosing 56 DAS# CRP 56 #mg QD [002] 56 cilostazol 56 Phase III randomized placebo 56 Initiated Phase 56 efficacy endpoint 56 sunitinib malate 56 genotypic resistance 56 AIR CF2 56 ACTIVE W 56 dose cohorts 56 boosted protease inhibitor 56 virological failure 56 irbesartan 56 mcg kg 56 randomized Phase 2b 56 Phase Ib clinical 56 MoxDuo IR 56 primary hypercholesterolemia 56 GSK# [001] 56 randomized controlled clinical 56 multidose 56 VIRAMUNE XR 56 QTc prolongation 56 evaluating tivozanib 56 multicenter study 56 ongoing Phase 1b 56 mcg doses 56 pegylated interferon alpha 56 EMPHASIS HF trial 56 multicenter clinical 56 RezularTM 56 virological response 56 phase IIa clinical 56 DMARD therapy 56 methotrexate monotherapy 56 prospectively stratified 56 TMC# r 56 Index CDAI 56 RSD# oral 56 azilsartan medoxomil 56 multicenter prospective 56 plus ribavirin 56 N#HSWD 56 telaprevir dosed 56 Maximum Tolerated Dose MTD 56 Randomized Double blind 56 BR.# 56 mcg BID 56 antiretroviral naive 56 CANCIDAS 56 dose regimen 56 EDEMA3 56 statistically significant efficacy 56 safety tolerability pharmacokinetic 56 ritonavir boosted atazanavir 56 phase IIb 56 intravenous dose 56 phase IIb trial 56 Folfox 56 multicenter randomized clinical 56 nadolol 56 CAMMS# 55 tenofovir emtricitabine 55 LEXIVA r 55 eplerenone 55 Secondary efficacy endpoints 55 melphalan prednisone 55 methotrexate therapy 55 NSABP B 55 secondary efficacy endpoint 55 abacavir lamivudine 55 Secondary endpoints 55 relapsed AML 55 peginterferon alfa 2a 55 retrospective observational study 55 CATIE AD 55 BRIM3 55 Phase Ib 55 Randomized Evaluation 55 corticosteroid dose 55 Phase 1b 55 prospectively randomized 55 unfractionated heparin UFH 55 crizotinib PF # 55 controlled multicenter Phase 55 octreotide LAR 55 lorcaserin Phase 55 #mg dosing group 55 Phase IIa 55 timepoint 55 Phase 2a clinical 55 virologic failure 55 DAPT 55 MoxDuo TM IR 55 adenoma recurrence 55 Phase 1a 55 Phase IIIb study 55 ZYBRESTAT fosbretabulin 55 randomization 55 aspartate aminotransferase AST 55 venlafaxine ER 55 risperidone Risperdal 55 mg qd 55 NO# [002] 55 salmeterol fluticasone 55 GetGoal Phase III 55 multicentre randomized controlled 55 stage IIIb IV 55 clinically meaningful improvements 55 STRIDE PD 55 DEB# 55 saline placebo 55 platinum refractory 55 evaluable subjects 55 viral kinetics 55 polysomnography PSG 55 label multicenter Phase 55 hemoglobin A1c levels 55 PegIFN RBV 55 phase 2a 55 autoantibody positive 55 subcutaneous injections 55 phase IIIb 55 Phase 2b clinical 55 Prograf R 55 placebo controlled multicenter 55 estramustine 55 randomized controlled clinical trials 55 maximally tolerated dose 55 INVEGA SUSTENNA 55 efavirenz EFV 55 intravenous IV infusion 55 IBS C 55 subanalysis 55 evaluable patients 55 pharmacologically active isomer 55 REVIVE Diabetes 55 aplindore 55 oral COTI 55 MEND CABG II 55 safety tolerability 55 Cloretazine R VNP#M 55 rFVIIa 55 Phase IIa trial 55 partial remissions 55 #mg/m# [002] 55 rt PA 55 label multicenter randomized 55 MERLIN TIMI 55 non inferiority 55 unblinding 55 prospective cohort 55 Dacogen injection 55 #mg QD [001] 55 citalopram 55 olmesartan 55 subcutaneous methylnaltrexone 55 LPV r 55 multicenter Phase 55 peg IFN 55 randomized Phase III 55 #mg q8h 55 trial evaluating PRX# 55 lacosamide 55 prespecified 55 sunitinib 55 nucleoside naive patients 55 doxorubicin docetaxel 55 mg TID 55 posttreatment 55 EDSS score 55 peginterferon alfa 2b 55 Phase #b/#a trial 55 metformin sulfonylurea 55 methacholine challenge 55 pharmacokinetic PK 55 TAXUS V 55 chlorambucil 54 evaluating Vectibix 54 Fx #A 54 trastuzumab Herceptin ® 54 Multicenter 54 5-FU/LV 54 #mg dose [001] 54 IFN alfa 54 FOLPI 54 Raptiva r 54 intravenous cyclophosphamide 54 Phase Ia 54 sirolimus eluting stent 54 pharmacodynamics PD 54 #mg dose [003] 54 NOX E# 54 LUX Lung 54 Phase IIB 54 subcutaneous dose 54 Polyp Prevention Trial 54 #mg BID [001] 54 Randomized Double Blind 54 biphasic insulin aspart 54 antihypertensive therapy 54 oxycodone CR 54 bosentan 54 IV bolus 54 unique alkylating agent 54 monotherapy 54 tacrolimus ointment 54 OMS# 54 CR nPR 54 chemoradiation therapy 54 CAELYX 54 ascending dose study 54 Proellex TM 54 ADL# 54 BoNTA 54 morphometric vertebral fractures 54 mcg albinterferon alfa 2b 54 Insulin PH# 54 nadroparin 54 hypogonadal men 54 pyridostigmine 54 Doxil ® 54 docetaxel prednisone 54 HBeAg negative patients 54 Adalimumab 54 Phase Ib study 54 fluvastatin 54 undetectable HCV RNA 54 pharmacodynamic profile 54 titration 54 Apidra ® 54 Phase IIa trials 54 Multicenter Randomized Double 54 Phase Ib II 54 subcutaneous SC 54 Phase III metastatic melanoma 54 Phase Ib IIa 54 clomipramine 54 pharmacodynamic PD 54 evaluable 54 Sorafenib HCC Assessment 54 FOLFOX 54 latrepirdine 54 landmark ATHENA study 54 systemic ALCL 54 insulin degludec 54 ATACAND 54 ECASS 54 Carotid Revascularization Endarterectomy vs. 54 pramlintide 54 adalimumab 54 fluticasone furoate 54 lanthanum carbonate 54 OADs 54 RG# [001] 54 mg Pycnogenol 54 dalteparin 54 pivotal bioequivalence 54 Pegasys ® 54 neoadjuvant 54 Phase III multicenter 54 ritonavir boosted protease inhibitor 54 dacarbazine 54 Phase #b/#a 54 EXPAREL TM 54 somatostatin analog 54 coadministration 54 nucleoside analog 54 DMARD 54 Phase IIb randomized 54 #mg BID [003] 54 decitabine 54 dexmedetomidine 54 confirmatory Phase III 54 lispro 54 ritonavir boosted lopinavir 54 pharmacodynamic effects 54 adjunctive ABILIFY 54 HbA1c levels 54 SCIg 54 MAGE A3 ASCI 54 mg RDEA# 54 underwent liver transplantation 54 glycoprotein IIb IIIa inhibitor 54 Onrigin 54 ANCHOR trial 54 composite endpoint 54 budesonide MMX 54 dose limiting toxicities 54 hour bronchodilation 54 diabetic neuropathic pain 54 gemcitabine carboplatin 54 QTcF 54 Phase IIa clinical 54 spontaneous bowel movements 54 brivaracetam 54 rotigotine 54 investigational protease inhibitor 54 colesevelam HCl 54 amoxicillin clavulanate 54 adefovir treated 54 APPRAISE 54 Placebo Controlled Study 54 TPV r 54 protease inhibitor PI 54 FAME Study 54 ACTEMRA TM 54 controlled dose escalation 54 phase IIb study 54 4mg/kg 54 Flu Cy 54 oral ridaforolimus 54 Phase #/#a 54 plus methotrexate 54 peritumoral brain edema 54 #mg/m# [001] 54 paclitaxel poliglumex 54 TEAEs 54 Phase 2a trial 54 Clinical Antipsychotic Trials 54 Prograf ® 54 Peg IFN 54 ALT flares 54 postmenopausal osteoporotic women 54 placebo PBO 54 valsartan amlodipine 54 heFH 54 budesonide formoterol 54 randomly assigned 54 CLARITY study 54 warfarin therapy 54 mg Proellex 53 oral sapacitabine 53 bepotastine besilate nasal spray 53 Phase 2b trial 53 acute mania 53 glargine 53 factorial design 53 mg/m2/day 53 nitazoxanide 53 Phase 1a clinical 53 mapatumumab 53 FOLFIRI 53 Engerix B 53 nodular partial response 53 TTF Therapy 53 APEX PD 53 HBeAg positive 53 randomized controlled trial 53 TYKERB 53 canakinumab 53 alfa 2a 53 incontinence episodes 53 ACR Pedi 53 XL# SAR# 53 bicifadine 53 intra articular injection 53 Tolvaptan 53 ABC/3TC 53 ZOLINZA 53 INCB# [001] 53 mcg QD 53 Bayer HealthCare Onyx Pharmaceuticals 53 Phase IIIb clinical 53 aflibercept 53 PEG Intron ® 53 azacitidine 53 eribulin mesylate 53 multicenter phase 53 mg subcutaneous injection 53 AGILECT R 53 pharmacokinetic 53 Perforomist Inhalation Solution 53 Phase 1b trial 53 QTc 53 haematologic 53 KRAS mutations occur 53 pharmacodynamics 53 GATTEX ® 53 virologic 53 carboplatin paclitaxel 53 beta2 agonist 53 microgram kg 53 REYATAZ r arm 53 pramipexole 53 flutamide 53 IIa trial 53 ancrod 53 Phase III Clinical Trials 53 Fludara 53 daily subcutaneous injections 53 doxorubicin cyclophosphamide 53 antiretroviral regimen 53 epoetin alpha 53 dexamethasone Decadron 53 rFSH 53 NCT# ClinicalTrials.gov 53 clinically meaningful improvement 53 NPH insulin 53 maximal dose 53 pegylated interferon alfa 53 guanfacine 53 q8h 53 aromatase inhibitor therapy 53 rilonacept 53 μg kg 53 lixisenatide 53 prospectively enrolled 53 postoperative chemotherapy 53 pregabalin 53 LANTUS R 53 fallopian tube cancers 53 subcutaneous doses 53 capecitabine Xeloda R 53 caspofungin 53 GEM OS1 53 NLX P# 53 baseline HbA1c 53 histrelin 53 Randomized Controlled 53 Androxal TM 53 forodesine 53 remission CR 53 Pharmacokinetic parameters 53 randomized blinded placebo 53 dirucotide MBP# 53 TNF alpha inhibitor 53 3TC lamivudine Epivir 53 idraparinux 53 paroxysmal AF 53 EOquin TM 53 pertuzumab 53 superficial bladder cancer 53 randomized multicenter Phase III 53 NOXAFIL Oral Suspension 53 pegylated interferon peg IFN 53 placebo dexamethasone 53 C1 INH 53 olmesartan medoxomil 53 mg doses 53 LCP Tacro ™ 53 goserelin 53 continuous intravenous infusion 53 LATUDA 53 Placebo Controlled 53 Lamictal XR 53 #mg doses [002] 53 topically administered 53 certolizumab 53 polysomnogram 53 polysomnographic 53 pegylated interferon 53 events AEs 53 relapsing remitting multiple sclerosis 53 pharmacokinetic pharmacodynamic 53 metastatic renal cell carcinoma 53 Phase IIb trial 53 mg/m2 IV 53 % CI #.#-#.# [003] 53 dose escalations 53 Pred Forte 53 TDF FTC 53 Randomized Phase II 53 cytogenetic response 53 adenotonsillectomy 53 pimecrolimus cream 53 mg subcutaneously 53 rimonabant #mg 53 riociguat 53 ALN VSP Phase 53 peginterferon alfa 2a #KD 53 μg dose 53 tipranavir r 53 undetectable HBV DNA 53 Anturol TM 53 olanzapine LAI 53 oblimersen 53 #.#g/day 53 tiotropium 53 BENICAR 53 SCH # 53 LIALDA 53 unresectable HCC 53 MEND CABG 53 liposomal formulation 53 tolerability pharmacokinetics 53 aflibercept VEGF Trap 53 Teriflunomide 53 Ophena TM 53 preserved LVEF 53 LCP Tacro 53 ribavirin therapy 53 zolmitriptan 53 L PPDS 53 ENDEAVOR II 53 opioid induced bowel dysfunction 53 non splenectomized 53 ug kg 53 R# #mg BID 53 REG1 53 diuretic chlorthalidone 53 eculizumab therapy 53 CRp 53 INVEGA ® 53 Val HeFT 53 glycated hemoglobin levels 53 vicriviroc 53 temsirolimus 53 immunomodulatory therapy 53 inactive placebo 53 Xanafide 53 MoxDuo ® IR 53 serum HBV DNA 53 EVEREST II 53 Phase IIA 53 TELCYTA 53 alpha blocker 53 PEG INTRON R 53 generation purine nucleoside 53 dose placebo controlled 53 Amrubicin 53 posaconazole 53 icatibant 53 FOSRENOL ® 53 paliperidone ER 52 Pooled Analysis 52 plus dexamethasone 52 miglustat 52 n = 52 Corlux 52 R#/MEM # 52 PegIntron 52 relapsing multiple sclerosis 52 LUMINATE 52 iniparib BSI 52 dietary questionnaires 52 Oral Fingolimod 52 APTIVUS 52 budesonide pMDI 52 ENDEAVOR IV 52 NYHA functional class 52 biliary tract cancer 52 null responder HCV 52 TAXUS VI 52 postprocedure 52 ONGLYZA saxagliptin 52 retinal vein occlusion induced 52 placebo capsules 52 Phase IIb III 52 endoscopic remission 52 overt nephropathy 52 insulin lispro 52 Panzem R NCD 52 Pioglitazone 52 systemic corticosteroid 52 BYSTOLIC 52 Eloxatin R 52 comparing XIENCE V 52 Butrans 52 receptor tyrosine kinase inhibitor 52 nonmetastatic prostate cancer 52 tolerability profiles 52 plus gemcitabine 52 ocular hypertension 52 tocilizumab 52 seliciclib 52 eptifibatide 52 Wisconsin Sleep Cohort 52 confirmatory clinical 52 ALGRX 52 ORMD 52 Phase IIb clinical trials 52 paricalcitol 52 #mg ATC 52 Sym# 52 phase III ACCLAIM 52 conditional logistic regression 52 statistically significant improvement 52 ExTRACT TIMI 52 peginterferon alfa 52 levetiracetam 52 hepatic metastases 52 pharmacokinetic parameters 52 GOUT 52 LibiGel Phase III 52 intravitreal injections 52 INTERCEPT platelets 52 Ceplene/IL-2 52 tipranavir ritonavir 52 cetrorelix 52 KRN# 52 relapsed refractory AML 52 Phase 2b 52 UKPDS 52 oral prednisone 52 concurrent chemoradiation 52 NN# [001] 52 pharmacokinetic PK study 52 detectable HCV RNA 52 TMC# [002] 52 IV NSCLC 52 walk distance 6MWD 52 Arikace 52 Neovascular AMD 52 calculated creatinine clearance 52 glatiramer acetate 52 Phase III VISTA 52 paclitaxel carboplatin 52 treatment naïve genotype 52 prior chemotherapy regimens 52 RESIST studies 52 dose cytarabine 52 cisplatin vinorelbine 52 Enzastaurin 52 CCyR 52 intravenous picoplatin 52 dose dexamethasone 52 HSCT 52 PreCISe study 52 neurologic progression 52 AVERROES 52 vidofludimus 52 RECORD1 52 prospective multicentre 52 IFN beta 52 Kaplan Meier estimate 52 VAPRISOL 52 nulliparous women 52 metreleptin 52 RG# ITMN 52 moderate renal impairment 52 REMINYL ® 52 remission induction 52 pivotal Phase 52 naïve HCV 52 Decitabine 52 Subgroup analysis 52 preintervention 52 MADIT II 52 alvespimycin 52 Phase 2a 52 LCP AtorFen 52 refractory NSCLC 52 Testosterone MDTS ® 52 chemoradiotherapy 52 Phase III confirmatory 52 prospective observational cohort 52 intravenous RSD# 52 QD dosing 52 serum phosphorous 52 Fibromyalgia Impact Questionnaire 52 Aflibercept 52 TBC# 52 HCD# [002] 52 #mg dose [002] 52 AIR2 Trial 52 refractory metastatic colorectal cancer 52 MEVACOR 52 TAXOTERE R 52 anti arrhythmic 52 mg m² 52 Complications Trial 52 gadobutrol 52 MADRS score 52 ganetespib 52 DDP# 52 pretreatment baseline 52 relapsing remitting MS 52 achieved CCyR 52 exploratory endpoints 52 polysomnography 52 GATTEX ™ 52 basal insulin 52 intraocular inflammation 52 lopinavir r 52 prucalopride 52 pharmacokinetics pharmacodynamics 52 recurrent VTE 52 Denufosol 52 pharmacokinetic profiles 52 CYT# QbG# 52 randomized discontinuation 52 GnRH agonist 52 CLL8 52 bendamustine 52 underwent CABG 52 subcutaneous enoxaparin 52 insulin glulisine 52 PD LID 52 lamotrigine 52 rhIGF-I/rhIGFBP-3 52 PEARL SC 52 albiglutide 52 mRCC 52 Seliciclib 52 attain statistical significance 52 pivotal Phase III 52 TMC# [001] 52 oral antidiabetic medication 52 ixabepilone 52 Xelox 52 evaluating REVLIMID 52 tolvaptan 52 Tarceva TM 52 Multiple Ascending Dose 52 Pharmacokinetic 52 NATRECOR R 52 Thrombolysis 52 PREZISTA rtv 52 basal bolus regimen 52 virologic response 52 pharmacodynamic properties 52 COMFORT II 52 lopinavir r arm 52 intravesical 52 argatroban 52 PRE SURGE 52 Safinamide 52 Q#IR 52 Prospective Randomized 52 pegylated interferon alfa 2a 52 inhaled iloprost 52 HF ACTION 52 Indacaterol 52 Sapacitabine 52 biochemical relapse 52 Study ADX# 52 ARB telmisartan 52 trastuzumab emtansine T DM1 52 MVax R 52 ORENCIA ® 52 O PPDS 52 etanercept 52 modified REGENESIS Phase IIb 52 ibandronate 52 mg q8h 52 RSD# 52 5mg/kg 52 longitudinal cohort study 52 symptomatic VTE 52 SNT MC# 52 q#h 52 Twinrix 52 relapsed refractory multiple myeloma 52 Acute Decompensated Heart Failure 52 Tekamlo 52 analgesic efficacy 52 EINSTEIN DVT 52 infliximab monotherapy 52 ENGAGE AF TIMI 52 Solulin 52 nondiabetic patients 52 asthma exacerbation 52 Phase IIb clinical 52 timolol 52 relapsed APL 52 PRX # 52 VELCADE melphalan 52 COPAXONE R 52 REYATAZ r 52 plus Copegus R 52 prospective observational studies 52 ARIKACE 52 abatacept 52 rosuvastatin